Biodexa Pharmaceuticals PLC

Contributing Author

Recent Articles by Biodexa Pharmaceuticals PLC

Jun-30	Result of Annual General Meeting BDRX GlobeNewswire
Jun-30	Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants BDRX GlobeNewswire
Jun-29	Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress BDRX GlobeNewswire
Jun-17	Postponement and Re-scheduling of Annual General Meeting BDRX GlobeNewswire
May-14	Biodexa issues letter to Shareholders BDRX -8.48% GlobeNewswire
Apr-02	Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies BDRX +42.23% GlobeNewswire
Mar-27	Preliminary Results for the Year Ended 31 December 2025 BDRX BDRX -6.50% GlobeNewswire
Mar-23	Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group BDRX GlobeNewswire
Mar-18	ADR Ratio Change BDRX BDRX -10.92% GlobeNewswire
Mar-09	Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients BDRX GlobeNewswire
Feb-04	Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST BDRX -11.04% GlobeNewswire
Jan-05	Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary BDRX GlobeNewswire
Dec-18	Biodexa Announces Pricing of $10 Million Public Offering BDRX -23.99% GlobeNewswire
Dec-01	Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP BDRX GlobeNewswire
Nov-24	Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP BDRX GlobeNewswire
Nov-03	Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion BDRX GlobeNewswire
Oct-06	Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA - IGC Conference on October 11, 2025 BDRX GlobeNewswire
Sep-12	Interim results for the six months ended June 30, 2025 BDRX GlobeNewswire
Aug-18	Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) BDRX GlobeNewswire
Jul-31	ADR Ratio Change Effective BDRX -9.11% GlobeNewswire
Jul-15	ADR Ratio Change BDRX -10.21% GlobeNewswire
Jul-14	Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) BDRX +12.13% GlobeNewswire
Jun-27	Results of Annual General Meeting BDRX -6.21% GlobeNewswire
Jun-25	Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) BDRX GlobeNewswire
Jun-23	Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) BDRX +6.22% GlobeNewswire
Jun-11	Result of General Meeting BDRX GlobeNewswire
Jun-04	Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes BDRX GlobeNewswire
May-30	Shareholder Update BDRX GlobeNewswire
May-22	Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Notice of General Meeting BDRX +6.92% BDRX -17.27% GlobeNewswire
May-22	Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M BDRX +6.92% GlobeNewswire
May-12	Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP BDRX -12.77% GlobeNewswire
May-02	Result of General Meeting BDRX GlobeNewswire

Biodexa Pharmaceuticals PLC

Recent Articles by Biodexa Pharmaceuticals PLC

Upgrade your Finviz experience